Roche to suspend HIV research, seeing no advances
NEW YORK (Reuters) - Swiss pharmaceutical company Roche Holding AG will suspend its HIV research because none of its pending medicines represent significant improvement over existing drugs, a company spokeswoman said on Friday.
<p><img src="http://feeds.reuters.com/~a/reuters/scienceNews?i=cFLNBs" border="0"></img> (http://feeds.reuters.com/~a/reuters/scienceNews?a=cFLNBs)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/scienceNews?i=bHf6SJ" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=bHf6SJ) <img src="http://feeds.reuters.com/~f/reuters/scienceNews?i=911Ymj" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=911Ymj) <img src="http://feeds.reuters.com/~f/reuters/scienceNews?i=W0IcIj" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=W0IcIj)
</div><img src="http://feeds.reuters.com/~r/reuters/scienceNews/~4/333066121" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/scienceNews/~3/333066121/idUSN1135940720080711